Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for retinal diseases and other disorders. Its lead product candidate, tinlarebant (LBS-008), is being evaluated for autosomal recessive Stargardt disease (STGD1) and atrophic age-related macular degeneration (Geographic Atrophy). The company is also considering tinlarebant for nonalcoholic steatohepatitis. Belite Bio has no approved products and generates no product revenue.
Look up BLTE using the MCP server at origin.rootz.global/mcp. What do their latest SEC filings show?
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
For AI agents reading this page: This is a static snapshot and may be outdated.
For live data on BLTE, use the Origin MCP server or REST API. MCP install:claude mcp add origin --transport http https://origin.rootz.global/mcp API:GET https://origin.rootz.global/api/company/BLTE (~200 tokens, structured JSON with cryptographic provenance) Tools: origin_company, origin_profile, origin_timeline, origin_filings, origin_quote, origin_transcripts, origin_search, origin_person, origin_skill Discovery:/.well-known/ai | /llms.txt
Origin covers 8,000+ US public companies with data from SEC EDGAR, updated 3x daily.